S1079
Clinical – Upper GI
ESTRO 2026
across 10 Italian centers. Prescription doses ranged from 30 to 50 Gy in 3–6 sessions. Collected data included biologically effective dose (BED10), target volume margins, systemic therapy, CA 19-9 levels, and treatment-related effects (graded using CTCAE v5.0). MR-guided SBRT (MRgRT) was used in 74,2% of cases. Imaging response was assessed using CT, MRI, or PET at baseline and post-treatment Results: Median BED10 was 85.9 Gy (range: 59.5–140.7). MRgRT patients showed improved duodenal protection (V33 < 0.5 cc in 91% vs 74% with conventional SBRT). Moderate treatment-related effects (grade ≥ 2) occurred in 13.6% of patients, with no severe gastrointestinal events (grade ≥ 3) in the MRgRT subgroup. Radiological partial response was observed in 45% of patients, and stable disease in 35%. A reduction in CA 19-9 greater than 50% was noted in 60% of evaluable cases. Median follow-up was 13.2 months. One-year local control was 82%, with no significant difference between MRgRT and conventional SBRT. Conclusion: SBRT for pancreatic tumors is feasible and well- tolerated across multiple Italian centers. MRgRT may offer advantages in protecting healthy tissue and reducing treatment-related effects. These findings support broader integration of MRgRT and standardized imaging protocols in pancreatic SBRT. References: 1.Herman JM, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–1137.2.Rudra S, et al. Using adaptive magnetic resonance image–guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123–2132.3.Chuong MD, et al. Ablative 5-fraction stereotactic magnetic resonance– guided radiation therapy for inoperable pancreatic cancer using online adaptive planning. Pract Radiat Oncol. 2021;11(5):e558–e567.4.Reyngold M, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7(5):735–738. Keywords: Pancreatic cancer, SBRT, Clinical outcomes
Thoracic RT for EC was associated with significantly increased risks of new-onset IHD, cerebrovascular events, and their composite, suggesting clinically relevant late vascular toxicity involving both coronary and cerebrovascular territories. These findings support minimizing radiation dose to critical vascular structures, optimizing cardiovascular risk factor management, and implementing long-term cardio- and neurovascular surveillance in patients receiving RT for esophageal cancer. Keywords: Esophageal cancer, CVA risk Multicenter Analysis of Pancreatic SBRT in 356 Patients: Clinical Outcomes, Treatment-Related Effects, and Imaging Response Across Italian Centers Rita Marina Niespolo 1 , Marco Lupatelli 2 , Luca Nicosia 3 , Eliana La Rocca 4 , Angela Romano 5 , Alessia Surgo 6 , Alessandra Arcelli 7 , Bruno Meduri 8 , Sabrina Montrone 9 , Giampaolo Montesi 10 , Elena Galofaro 11 , Francesca De Felice 12 , Pierfrancesco Franco 13 , Andrea D'Aviero 14 , Fernando Munoz 15 , Filippo De Renzi 16 1 radiation oncology, IRCCS-San Gerardo.it, Monza, Digital Poster Highlight 1906 Italy. 2 radiation oncology, Santa Maria della Misericordia Hospital, Perugia, Italy. 3 radiation oncology, IRCCS-San Gerardo.it, Verona, Italy. 4 radiation oncology, Integrated University Hospital Company of Verona, Verona, Italy. 5 radiation oncology, Policlinico Gemelli,, Roma, Italy. 6 radiation oncology, “F. Miulli” Hospital, Acquaviva delle Fonti (BA), Italy. 7 radiation oncology, Ospedale Malpighi, Bologna, Italy. 8 radiation oncology, University Hospital of Modena, Modena, Italy. 9 radiation oncology, Pisa University Hospital Company, Pisa, Italy. 10 radiation oncology, AST Pesaro Urbino – San Salvatore Hospital, Pesaro, Italy. 11 radiation oncology, Riuniti Hospitals of Ancona, Ancona, Italy. 12 radiation oncology, Sapienza University of Rome, Roma, Italy. 13 radiation oncology, Major Hospital of Charity, Novara, Italy. 14 radiation oncology, University of Studies "G. d'Annunzio", Chieti, Italy. 15 radiation oncology, Hospital Parini of Aosta, Aosta, Italy. 16 radiation oncology, Belluno Hospital, Belluno, Italy Purpose/Objective: To evaluate clinical outcomes, treatment-related effects, and imaging response in a large multicenter Italian cohort of patients treated with stereotactic body radiotherapy (SBRT) for pancreatic tumors, including both MR-guided and conventional techniques. Material/Methods: A retrospective analysis was conducted on 356 patients treated with SBRT between 2021 and 2025
Digital Poster 1947
Definitive chemoradiotherapy for esophageal cancer: comparison of radiation dose, side effects and survival in a multicenter cohort study Halla Sif Olafsdottir 1,2 , Theodora Run Baldursdottir 3 , Magnus Nilsson 2,4 , Gabriella Alexandersson von Döbeln 1,2 , Mats Lindblad 2,4
Made with FlippingBook - Share PDF online